Therapy for isocitrate dehydrogenase 2 (IDH2) R172 -mutant acute myeloid leukaemia.

Autor: Linch DC; Department of Haematology, University College London (UCL) Cancer Institute, London, UK., Hills RK; Nuffield Department of Population Health, University of Oxford, Oxford, UK., Burnett AK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK., Russell N; Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK., Gale RE; Department of Haematology, University College London (UCL) Cancer Institute, London, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2022 Mar; Vol. 196 (6), pp. 1348-1352. Date of Electronic Publication: 2021 Dec 06.
DOI: 10.1111/bjh.17981
Abstrakt: Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2) R172 -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2 WT and IDH2 R140 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2 R172 AML. We found an improved outcome for IDH2 R172 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.
(© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: